On July 7, QingSong Health rose 10.14% in regular trading, trading at HKD 10.42/share, with turnover of HKD 134 million.

On the news front, QingSong Health's proprietary evidence-based medicine AI agent \"MedClaw\" was selected as a typical case in the AI-Empowered Scenario Applications collection at the Global Digital Economy Conference, marking the company's medical AI transition from model demonstration to real-world scenario validation. MedClaw has launched over 2,000 standardized Skills covering nine core medical scenarios and has passed all 13 functional use case evaluations by the China Academy of Information and Communications Technology.

Additionally, the company is executing an up to HKD 100 million share buyback program. On July 2, QingSong Health repurchased 2.972 million shares in a single day at prices between HKD 9.69 and HKD 10.74, paying approximately HKD 29.89 million. As of the latest disclosure, the company has repurchased a cumulative 5.012 million shares under the authorization, with approximately 15.63 million shares remaining available for repurchase, continuing to signal confidence to the market.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)